ICU (SeaStar Medical Holding) Pretax Margin %: -710.71% (As of Mar. 2026)


ICU SeaStar Medical Holding Corp ICU
31 GF Score
Price $3.18
! 4 Warning Signs
View Full Analysis

What is SeaStar Medical Holding Pretax Margin %?

SeaStar Medical Holding ICU +4.70% 31 Pretax Margin % is -710.71% as of Mar. 2026. GuruFocus rates ICU with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 946 Biotechnology companies, SeaStar Medical Holding ranks worse than 76.64% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. SeaStar Medical Holding's Pre-Tax Income for the three months ended in Mar. 2026 was $-3.52 Mil. SeaStar Medical Holding's Revenue for the three months ended in Mar. 2026 was $0.50 Mil. Therefore, SeaStar Medical Holding's pretax margin for the quarter that ended in Mar. 2026 was -710.71%.

The historical rank and industry rank for SeaStar Medical Holding's Pretax Margin % or its related term are showing as below:

ICU' s Pretax Margin % Range Over the Past 10 Years
Min: -18390.37   Med: -9687.37   Max: -828.41
Current: -828.41


ICU's Pretax Margin % is ranked worse than
76.64% of 946 companies
in the Biotechnology industry
Industry Median: -90.5 vs ICU: -828.41

SeaStar Medical Holding  (NAS:ICU) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


SeaStar Medical Holding Pretax Margin % Related Terms


SeaStar Medical Holding Pretax Margin % Historical Data

* Premium members only.

The historical data trend for SeaStar Medical Holding's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SeaStar Medical Holding Pretax Margin % Chart

SeaStar Medical Holding Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Pretax Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 -18,390.37 -984.36

SeaStar Medical Holding Quarterly Data
Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,286.35 -592.31 -1,897.27 -691.43 -710.71

ICU vs MBRX, LEXX, INTI: Pretax Margin % Comparison

For the Biotechnology subindustry, SeaStar Medical Holding's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SeaStar Medical Holding Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SeaStar Medical Holding's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where SeaStar Medical Holding's Pretax Margin % falls into.


ICU
31GF Score
SeaStar Medical Holding Corp ICU
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SeaStar Medical Holding Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

SeaStar Medical Holding's Pretax Margin for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-12.147/1.234
=-984.36 %

SeaStar Medical Holding's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-3.518/0.495
=-710.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of -710.71% mean?
SeaStar Medical Holding (ICU) has a Pretax Margin % of -710.71% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on SeaStar Medical Holding and its competitors. According to the industry distribution chart, SeaStar Medical Holding ranks #725 out of 946 companies in the Biotechnology industry, placing it in the top 76.6%.
Is SeaStar Medical Holding's Pretax Margin % too high?
SeaStar Medical Holding's current Pretax Margin % is -710.71%. Based on the distribution chart, SeaStar Medical Holding ranks #725 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SeaStar Medical Holding has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does SeaStar Medical Holding's Pretax Margin % compare to MBRX and LEXX?
According to the Biotechnology industry distribution chart, SeaStar Medical Holding ranks #725 out of 946 companies for Pretax Margin %. This places SeaStar Medical Holding in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on SeaStar Medical Holding and its competitors. SeaStar Medical Holding's current Pretax Margin % is -710.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SeaStar Medical Holding stock overvalued right now?
SeaStar Medical Holding (ICU) has a current Pretax Margin % of -710.71%. The current Pretax Margin % is -710.71%. SeaStar Medical Holding's overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For SeaStar Medical Holding (ICU), the current Pretax Margin % is -710.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SeaStar Medical Holding Business Description

Address 3513 Brighton Boulevard, Suite 410, Denver, CO, USA, 80216
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
31GF Score

Get the complete analysis for ICU

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.18
Price